about
Warburg effect, hexokinase-II, and radioresistance of laryngeal carcinomaRalBP1 and p19-VHL play an oncogenic role, and p30-VHL plays a tumor suppressor role during the blebbishield emergency program.Identification of a suitable qPCR reference gene in metastatic clear cell renal cell carcinoma.Overexpression of metabolic markers HK1 and PKM2 contributes to lymphatic metastasis and adverse prognosis in Chinese gastric cancer.FLIP(L) is critical for aerobic glycolysis in hepatocellular carcinoma.Hexokinase 2 enhances the metastatic potential of tongue squamous cell carcinoma via the SOD2-H2O2 pathway.Metabolic Modification in Gastrointestinal Cancer Stem Cells: Characteristics and Therapeutic Approaches.Therapeutic Strategies for Hereditary Kidney Cancer.Renal cell carcinoma: the search for a reliable biomarker.Pyruvate kinase M2 deregulation enhances the metastatic potential of tongue squamous cell carcinoma.High expression of Aldolase A predicts poor survival in patients with clear-cell renal cell carcinoma.Transcriptome analysis of human colorectal cancer biopsies reveals extensive expression correlations among genes related to cell proliferation, lipid metabolism, immune response and collagen catabolism.Discovery and Optimization of Potent, Cell-Active Pyrazole-Based Inhibitors of Lactate Dehydrogenase (LDH).The role of metabolic enzymes in mesenchymal tumors and tumor syndromes: genetics, pathology, and molecular mechanisms.Therapeutic potential of targeting glucose metabolism in glioma stem cells.High glucose enhances the metastatic potential of tongue squamous cell carcinoma via the PKM2 pathway.LY294002 inhibits the Warburg effect in gastric cancer cells by downregulating pyruvate kinase M2.SDH-deficient renal cell carcinoma associated with biallelic mutation in succinate dehydrogenase A: comprehensive genetic profiling and its relation to therapy response.Hereditary Renal Tumor Syndromes: Update on Diagnosis and Management.Butein Inhibited In Vitro Hexokinase-2-Mediated Tumor Glycolysis in Hepatocellular Carcinoma by Blocking Epidermal Growth Factor Receptor (EGFR).
P2860
Q28072714-4E081CF8-6971-4140-9D1A-068A823F299CQ33292271-79B13371-44E5-4EEE-B7B8-2A37F2105C86Q34767097-A005FF80-461E-46FD-A9B6-74EF91076F6DQ36095239-A16E08B2-2E34-4E04-BF2D-F7CE15EF48F5Q36898471-1D9AE3E5-24F1-4510-9E14-74A4471C6D26Q37709470-C0518272-2A54-48E8-8108-23F5B527DB49Q38704618-F6EE5B08-1214-44F2-A0D9-11768174851EQ38871343-460AFF7A-97AB-4A2C-96B4-D83CDEC2FC81Q41197945-12DC82C9-A767-44DB-B418-AFE6B0FA5685Q41844362-0698A5E4-A6FF-4F89-ACF4-D8FD69168635Q42318068-39201DF7-0206-4F41-BFC6-4C33BF946346Q45894388-34A2422C-1AB0-4DEA-AD6E-810B3212DF69Q47626141-6DF4957E-1413-4F38-9BC7-49626E422AE0Q47728815-9CA98F06-9FF3-45A8-9B57-242F66BDFFBBQ48628647-514CC9C4-E7ED-4835-AE80-171965423226Q50017133-A76D7841-5A5C-495E-8961-9E0FFFE4302DQ54121259-47328BC4-F4A2-4EF5-81F0-AD8C09E11E7EQ54976922-BFEDF2A1-B1B7-45B2-996D-4F280BCF297CQ55083786-D30149B5-7EF5-48F9-A472-A8373AFC23F5Q55368961-9C049534-6E4C-4805-BE72-35C60BA64052
P2860
description
2013 nî lūn-bûn
@nan
2013 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Aerobic glycolysis: a novel target in kidney cancer.
@ast
Aerobic glycolysis: a novel target in kidney cancer.
@en
Aerobic glycolysis: a novel target in kidney cancer.
@nl
type
label
Aerobic glycolysis: a novel target in kidney cancer.
@ast
Aerobic glycolysis: a novel target in kidney cancer.
@en
Aerobic glycolysis: a novel target in kidney cancer.
@nl
prefLabel
Aerobic glycolysis: a novel target in kidney cancer.
@ast
Aerobic glycolysis: a novel target in kidney cancer.
@en
Aerobic glycolysis: a novel target in kidney cancer.
@nl
P2093
P2860
P356
P1476
Aerobic glycolysis: a novel target in kidney cancer.
@en
P2093
Brian Shuch
Ramaprasad Srinivasan
W Marston Linehan
P2860
P304
P356
10.1586/ERA.13.57
P577
2013-06-01T00:00:00Z